IMMX News

Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025

Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting

Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference